Beta-Acetoxyisovalerylshikonin
Based on 1 publication(s) in Google Scholar
Beta-Acetoxyisovalerylshikonin is a naturally occurring naphthoquinone-type shikonin derivative that is widely distributed in the roots and cell suspension cultures of *Arnebia euchroma*, *Arnebia guttata*, *Onosma hispidum* and *Lithospermum erythrorhizon*. Beta-Acetoxyisovalerylshikonin exhibits favorable antibacterial, anti-inflammatory, wound-healing promoting and antioxidant activities, and also possesses potential anti-tumor and anti-HIV properties.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.57%
- CAS. Nr.: 69091-17-4
- Formel: C23H26O8
- Molecular Weight:430.45
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-N5112A
β,β-DimethylacrylalkanninFGFR1 Inhibitor -
HY-N2181
AcetylshikoninAnti-inflammatory agent, AChE Inhibitor, P450 Inhibitor, Neuroprotective agents -
HY-N4201
β-HydroxyisovalerylshikoninSrc Inhibitor -
HY-N2187
DeoxyshikoninAntibacterial Agent -
HY-N5112B
β,β-DimethylacrylshikoninAnticancer Compound -
HY-N2592
IsobutylshikoninShikonin Pigment -
HY-N0111
Coenzyme Q10Antioxidant -
HY-N0822
ShikoninChloride Channel Inhibitor -
HY-N6949
JugloneAntimicrobial Drug -
HY-N0111R
Coenzyme Q10 (Standard)Antioxidant -
HY-N0822R
Shikonin (Standard)Chloride Channel Inhibitor -
HY-N7610
AcetylalkanninBacterial Inhibitor
Publications Citing Use of MedChemExpress (MCE) Beta-Acetoxyisovalerylshikonin
More
Biologische Aktivität
Beschreibung
In Vitro
Beta-Acetoxyisovalerylshikonin (1 mg/mL, 10 mg/mL, 20 mg/mL, 100-300 ng/spot, 100-300 ng, 100-1800 ng; 30 min) was quantified via a validated HPTLC-densitometric method that enables precise, specific quantification in root extracts of Arnebia euchroma, Arnebia guttata, and Arnebia hispidissima (with no detection in Arnebia benthamii)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS. Nr. 69091-17-4
-
Appearance Solid
-
Molecular Weight 430.45
-
Formel C23H26O8
-
Color Brown to black
-
SMILES
CC(C)(OC(C)=O)CC(O[C@H](C(C1=O)=CC(C2=C1C(O)=CC=C2O)=O)C/C=C(C)\C)=O
-
Structure Classification
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 50 mg/mL (116.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.81 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Sharma N, et al. Isolation and purification of acetylshikonin and beta-acetoxyisovalerylshikonin from cell suspension cultures of Arnebia euchroma (Royle) Johnston using rapid preparative HPLC. J Sep Sci. 2008;31(4):629-635. [Content Brief]
[2]. Sharma N, et al. Simultaneous densitometric determination of shikonin, acetylshikonin, and beta-acetoxyisovaleryl-shikonin in ultrasonic-assisted extracts of four Arnebia species using reversed-phase thin layer chromatography. J Sep Sci. 2009;32(18):3239-3245. [Content Brief]
[3]. Yen CY, et al. Lithospermum erythrorhizon extract inhibits Der p2-induced inflammatory response through alleviation of thymic stromal lymphopoietin, nuclear factor Kappa B, and inflammasome expression in human bronchial epithelial cells. J Ethnopharmacol. 2017;201:1-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3232 mL | 11.6158 mL | 23.2315 mL | 58.0788 mL |
| 5 mM | 0.4646 mL | 2.3232 mL | 4.6463 mL | 11.6158 mL | |
| 10 mM | 0.2323 mL | 1.1616 mL | 2.3232 mL | 5.8079 mL | |
| 15 mM | 0.1549 mL | 0.7744 mL | 1.5488 mL | 3.8719 mL | |
| 20 mM | 0.1162 mL | 0.5808 mL | 1.1616 mL | 2.9039 mL | |
| 25 mM | 0.0929 mL | 0.4646 mL | 0.9293 mL | 2.3232 mL | |
| 30 mM | 0.0774 mL | 0.3872 mL | 0.7744 mL | 1.9360 mL | |
| 40 mM | 0.0581 mL | 0.2904 mL | 0.5808 mL | 1.4520 mL | |
| 50 mM | 0.0465 mL | 0.2323 mL | 0.4646 mL | 1.1616 mL | |
| 60 mM | 0.0387 mL | 0.1936 mL | 0.3872 mL | 0.9680 mL | |
| 80 mM | 0.0290 mL | 0.1452 mL | 0.2904 mL | 0.7260 mL | |
| 100 mM | 0.0232 mL | 0.1162 mL | 0.2323 mL | 0.5808 mL |
Beta-Acetoxyisovalerylshikonin Related Classifications
HY-N2188 Related Classifications
Powered by Bioz